Healthcare provider profile · identity verified

Jose Lares, MD

Allopathic & Osteopathic Physicians|Internal Medicine · WESLACO, TX · NPI 1407902182

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Jose Lares, MD received $162.32 in general payments during 2025 across 2 reported records.

ABBVIE INC. accounted for 77.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Linzess by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Ozempic by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$162.32

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ABBVIE INC.	Unresolved — no canonical attribution shown	$125.01	77.0%	1	2025
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$37.31	23.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$162.32	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
QULIPTA Normalized: qulipta	Drug	ABBVIE INC.	$125.01	1	2025
Source payment records 2025-08-28 · ABBVIE INC. · $125.01 · Open Payments source
Ozempic Normalized: ozempic	Drug	Novo Nordisk Inc	$37.31	1	2025
Source payment records 2025-06-04 · Novo Nordisk Inc · $37.31 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
Ozempic ozempic	2025	Ozempic	2024	138	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	CREON open payments reported associated product	CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608	Creon · 2024 Exact normalized brand match · 1 Part D row	11	suppressed by CMS
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	LINZESS open payments reported associated product	CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608	Linzess · 2024 Exact normalized brand match · 1 Part D row	81	40
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	SYNTHROID open payments reported associated product	CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636	Synthroid · 2024 Exact normalized brand match · 1 Part D row	38	15
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	138	43

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	946	384
Losartan Potassium	Losartan Potassium	700	261
Lisinopril	Lisinopril	520	201
Amlodipine Besylate	Amlodipine Besylate	507	204
Levothyroxine Sodium	Levothyroxine Sodium	494	186
Metformin Hcl	Metformin Hcl	449	184
Gabapentin	Gabapentin	380	172
Pantoprazole Sodium	Pantoprazole Sodium	360	135
Omeprazole	Omeprazole	358	144
Rosuvastatin Calcium	Rosuvastatin Calcium	354	148
Fluticasone Propionate	Fluticasone Propionate	305	139
Simvastatin	Simvastatin	290	112
Tamsulosin Hcl	Tamsulosin Hcl	253	112
Montelukast Sodium	Montelukast Sodium	252	94
Metoprolol Succinate	Metoprolol Succinate	244	108
Clopidogrel	Clopidogrel Bisulfate	237	94
Carvedilol	Carvedilol	225	79
Metoprolol Tartrate	Metoprolol Tartrate	213	80
Furosemide	Furosemide	202	82
Meloxicam	Meloxicam	200	70
Zolpidem Tartrate	Zolpidem Tartrate	200	40
Pioglitazone Hcl	Pioglitazone Hcl	193	85
Hydrochlorothiazide	Hydrochlorothiazide	186	62
Sertraline Hcl	Sertraline Hcl	174	74
Jardiance	Empagliflozin	164	67
Diclofenac Sodium	Diclofenac Sodium	161	72
Famotidine	Famotidine	154	78
Alprazolam	Alprazolam	145	39
Duloxetine Hcl	Duloxetine Hcl	145	51
Albuterol Sulfate Hfa	Albuterol Sulfate	142	51
Ozempic	Semaglutide	138	43
Pravastatin Sodium	Pravastatin Sodium	138	50
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	122	61
Mounjaro	Tirzepatide	122	30
Trazodone Hcl	Trazodone Hcl	110	43
Esomeprazole Magnesium	Esomeprazole Magnesium	103	39
Memantine Hcl	Memantine Hcl	103	42
Olmesartan Medoxomil	Olmesartan Medoxomil	100	38
Pregabalin	Pregabalin	100	37
Escitalopram Oxalate	Escitalopram Oxalate	99	35
Baclofen	Baclofen	97	35
Tradjenta	Linagliptin	93	30
Clonazepam	Clonazepam	85	17
Linzess	Linaclotide	81	40
Acetaminophen-Codeine	Acetaminophen With Codeine	80	24
Farxiga	Dapagliflozin Propanediol	80	27
Hydralazine Hcl	Hydralazine Hcl	80	32
Trulicity	Dulaglutide	78	19
Hydroxyzine Hcl	Hydroxyzine Hcl	75	41
Lorazepam	Lorazepam	75	14
Eliquis	Apixaban	74	27
Isosorbide Mononitrate Er	Isosorbide Mononitrate	73	26
Celecoxib	Celecoxib	72	25
Dutasteride	Dutasteride	71	26
Buspirone Hcl	Buspirone Hcl	70	32
Januvia	Sitagliptin Phosphate	70	25
Tramadol Hcl	Tramadol Hcl	69	28
Meclizine Hcl	Meclizine Hcl	68	32
Metformin Hcl Er	Metformin Hcl	66	28
Alendronate Sodium	Alendronate Sodium	65	28
Methadone Hcl	Methadone Hcl	64	13
Synjardy Xr	Empagliflozin/Metformin Hcl	64	20
Allopurinol	Allopurinol	63	27
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	63	25
Mirtazapine	Mirtazapine	63	26
Naproxen	Naproxen	63	20
Triamcinolone Acetonide	Triamcinolone Acetonide	62	29
Ondansetron Hcl	Ondansetron Hcl	60	22
Potassium Chloride	Potassium Chloride	58	24
Myrbetriq	Mirabegron	57	22
Finasteride	Finasteride	55	22
Fluoxetine Hcl	Fluoxetine Hcl	55	21
Ibuprofen	Ibuprofen	55	27
Latanoprost	Latanoprost	54	12
Nifedipine Er	Nifedipine	54	26
Benazepril Hcl	Benazepril Hcl	53	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	53	14
Prednisone	Prednisone	51	34
Ropinirole Hcl	Ropinirole Hcl	51	20
Sucralfate	Sucralfate	51	20
Ondansetron Odt	Ondansetron	50	16
Xarelto	Rivaroxaban	50	14
Donepezil Hcl	Donepezil Hcl	48	24
Cilostazol	Cilostazol	47	15
Mupirocin	Mupirocin	44	28
Levetiracetam	Levetiracetam	43	13
Oxycodone Hcl	Oxycodone Hcl	43	suppressed
Lovastatin	Lovastatin	42	13
Spironolactone	Spironolactone	42	16
Vitamin D2	Ergocalciferol (Vitamin D2)	41	19
Ezetimibe	Ezetimibe	40	17
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	40	11
Entresto	Sacubitril/Valsartan	38	16
Synthroid	Levothyroxine Sodium	38	15
Tresiba Flextouch U-200	Insulin Degludec	38	13
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	37	35
Janumet	Sitagliptin Phos/Metformin Hcl	36	15
Clonidine Hcl	Clonidine Hcl	35	13
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	34	22
Synjardy	Empagliflozin/Metformin Hcl	33	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	32	suppressed
Solifenacin Succinate	Solifenacin Succinate	32	12
Valsartan	Valsartan	32	14
Ammonium Lactate	Ammonium Lactate	31	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	31	15
Levemir Flexpen	Insulin Detemir	30	11
Tresiba Flextouch U-100	Insulin Degludec	30	13
Breo Ellipta	Fluticasone/Vilanterol	29	11
Dicyclomine Hcl	Dicyclomine Hcl	29	16
Icosapent Ethyl	Icosapent Ethyl	29	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	29	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	29	13
Atenolol	Atenolol	28	12
Tizanidine Hcl	Tizanidine Hcl	28	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	25	suppressed
Nystatin	Nystatin	25	suppressed
Belsomra	Suvorexant	24	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	24	suppressed
Citalopram Hbr	Citalopram Hydrobromide	23	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	23	suppressed
Jentadueto	Linagliptin/Metformin Hcl	23	suppressed
Levofloxacin	Levofloxacin	23	20
Sulfasalazine	Sulfasalazine	22	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	22	suppressed
Amoxicillin	Amoxicillin	21	19
Chlorthalidone	Chlorthalidone	21	suppressed
Febuxostat	Febuxostat	21	suppressed
Nabumetone	Nabumetone	21	suppressed
Nitroglycerin	Nitroglycerin	21	18
Rizatriptan	Rizatriptan Benzoate	21	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Ventolin Hfa	Albuterol Sulfate	21	12
Ciprofloxacin Hcl	Ciprofloxacin Hcl	20	16
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	20	suppressed
Constulose	Lactulose	19	11
Dexlansoprazole Dr	Dexlansoprazole	19	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	19	suppressed
Enalapril Maleate	Enalapril Maleate	19	suppressed
Nebivolol Hcl	Nebivolol Hcl	19	suppressed
Raloxifene Hcl	Raloxifene Hcl	19	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	19	suppressed
Vascepa	Icosapent Ethyl	19	suppressed
Bumetanide	Bumetanide	18	suppressed
Lactulose	Lactulose	18	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	18	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Azithromycin	Azithromycin	17	15
Glipizide	Glipizide	17	suppressed
Humulin R U-500 Kwikpen	Insulin Regular, Human	17	suppressed
Megestrol Acetate	Megestrol Acetate	17	suppressed
Telmisartan	Telmisartan	17	suppressed
Cefuroxime	Cefuroxime Axetil	16	15
Fenofibrate	Fenofibrate Nanocrystallized	16	suppressed
Fluconazole	Fluconazole	16	13
Glyxambi	Empagliflozin/Linagliptin	16	suppressed
Verapamil Er	Verapamil Hcl	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	14	suppressed
Folic Acid	Folic Acid	14	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	14	suppressed
Hydrocortisone	Hydrocortisone	14	12
Hydromorphone Hcl	Hydromorphone Hcl	14	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	13	suppressed
Captopril	Captopril	13	suppressed
Jantoven	Warfarin Sodium	13	suppressed
Lidocaine	Lidocaine	13	suppressed
Lubiprostone	Lubiprostone	13	suppressed
Methylprednisolone	Methylprednisolone	13	13
Morphine Sulfate	Morphine Sulfate	13	suppressed
Ursodiol	Ursodiol	13	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	13	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	12	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	12	suppressed
Labetalol Hcl	Labetalol Hcl	12	suppressed
Promethazine Hcl	Promethazine Hcl	12	suppressed
Ranolazine Er	Ranolazine	12	suppressed
Symbicort	Budesonide/Formoterol Fumarate	12	suppressed
Amiodarone Hcl	Amiodarone Hcl	11	suppressed
Creon	Lipase/Protease/Amylase	11	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Novolog Flexpen	Insulin Aspart	11	suppressed
Ofloxacin	Ofloxacin	11	suppressed
Procto-Med Hc	Hydrocortisone	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	11

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$162.32 · 2 records	ABBVIE INC.	Ozempic, QULIPTA	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Ozempic play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error